الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 54 |  |  |
| | | from | 54 | | |
Abstract
International collaborative study groups have led the way in defining the best approaches to local disease control, to reducing treatment related morbidity, and to optimizing long term functional outcomes. Our study aims at reviewing the management of GU-RMS cases in the last ten years. Twenty patients below 18 years were diagnosed with GU RMS during this period. charts were reviewed retrospectively. The overall survival for patients was 75 %, and the progression free survival was 65 %.
Patients’ age ranged from 9 months to 18 years, with a median of 9 years. Age had no significant effect on OS (p value = 0.502). 11 patients were male and 9 patients were female. 18 patients had favorable embryonal histopathology, and 2 patients only had alveolar histopathology but with no significant effect on OS (p value = 0.494). Ten patients (50%) had tumor size less than 5 cm. 7 patients (35%) had positive LNs, with an OS of 85.7 % , statistically it was insignificant (p value = 0.644) . Early stages of the tumor showed a good prognosis.
All cases received chemotherapy according to protocol being followed. 19 cases had initial diagnostic biopsy except for one case that had an upfront radical surgery. Following chemotherapy 8 patients had radical surgery. 14 patients received radiation therapy in the form of external beam radiation. At the end of study time 15 patients had no evidence of disease, while one patient was alive with disease. 4 patients died, three of them from the advanced stage of the disease and one patient due to severe neutropenia and septicemia.
In conclusion, RMS requires multidrug management including chemotherapy, surgery and radiotherapy is required to achieve the best survival outcome, without devastating effect on the quality of life.